Abraxis BioScience launches ‘Abraxane’ in the European Union

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, has announced the launch of Abraxane(R) Paclitaxel 5 mg/ml in the European Union.

In the EU, Abraxane(R) is indicated for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.

Nasdaq-listed Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses.